Behavioral Effects of Drugs (Inpatient): 40 [Methamphetamine, Methylphenidate, Duloxetine]

• Status: Recruiting
• Trial end date: 2021-07-30
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the behavioral effects of methamphetamine during maintenance on placebo, duloxetine, methylphenidate and duloxetine combined with methylphenidate using sophisticated human laboratory methods.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Craig Rush
• Collaborator: National Institute on Drug Abuse (NIDA)
• Treatments: Dopamine; Duloxetine Hydrochloride; Methamphetamine; Methylphenidate

Criteria

Inclusion Criteria:

• recent use of inhaled (i.e., snorted), smoked or injected methamphetamine

Exclusion Criteria:

• Abnormal screening outcome (e.g., ECG, blood chemistry result) that study physicians deem clinically significant.

• Current or past histories of substance use that are deemed by the study physicians to interfere with study completion.

• History of serious physical disease, current physical disease, impaired cardiovascular functioning, chronic obstructive pulmonary disease, history of seizure or current or past histories of serious psychiatric disorder that in the opinion of the study physician would interfere with study participation will be excluded from participation.

• Females not currently using effective birth control.

• Contraindications to methamphetamine, methylphenidate, or duloxetine.